At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 114 enrolled
Drug / intervention
G-CSF Granulocyte-Colony Stimulating Factor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Clinical Trial of Stem Cell Mobilization by Granulocyte-Colony-Stimulating Factor in Patients With Acute Myocardial Infarction. Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Trial
In Brief
A Phase 4 clinical trial evaluating G-CSF Granulocyte-Colony Stimulating Factor and Placebo for Myocardial Infarction. Completed, enrolled 114 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether stem cell mobilization by granulocyte colony-stimulating factor (G-CSF) therapy in patients with acute myocardial infarction after successful mechanical reperfusion reduces infarct size.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction
CountriesGermany
Timeline
Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
Study CompletionJul 2005
First PostedAug 2005
TodayJul 2026
First PostedAug 2, 2005
Enrollment StartFeb 1, 2004
Study CompletionJul 1, 2005
TodayJul 1, 2026
Posted 20.9 years ago
Interventions
G-CSF Granulocyte-Colony Stimulating Factordrug
Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
Placeboother
Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.